Publications

Publications 2026

March 2026

Addressing challenges along the ‘access cascade’ for new TB regimens

Authors: Servello, J. de Colombani, P. Dall’Olio, L. Gargioni, G. Raviglione, M.C.B. 
Source: IJTLD Open Vol 3 Issue 3
DOI: 10.5588/ijtldopen.25.0610

February 2026

Enhancing tuberculosis care in lower and middle-income countries through digital adherence technologies

Authors: Rabbyia Ahmad, João Pedro Ramos, Raquel Duarte, Christoph Lange,Job Van Rest
Source: Breathe 2026 22(1): 250173
DOI: 10.1183/20734735.0173-2025

February 2026

The role of the UNITE4TB Young Investigators Group in empowering early career researchers through mentorship, capacity building, and innovation

Authors: Vasiliu, A. Saluzzo, F. Schildkraut, J.A. Villar-Hernandez, R. Ramos, J.P. Vieira, M. Thwaites, G. Cirillo, D.M. Lange, C. Duarte, R.
Source: IJTLD Open, Vol 3, Issue 2
DOI: 10.5588/ijtldopen.25.0651

February 2026

Enhancing collaboration between national TB programmes and researchers

Authors: Dall’Olio, L. | de Colombani, P. | Servello, J. | Gargioni, G. | Duarte, R. | Raviglione, M. |
Source: IJTLD Open Vol 3 Issue 2 
DOI: 10.5588/ijtldopen.25.0624
 

27 January 2026

Management of adverse events in TB care and active TB drug safety monitoring

Authors: Shamsuddeen Yusuf Ma'aruf, Aparna Sharma, Shannon Fox, Raquel Duarte, Christoph Lange, Simon Tiberi, on behalf of the UNITE4TB Consortium
Source: Breathe 2026 22(1): 250203
DOI: 10.1183/20734735.0203-2025
 

Publications 2025

18 November 2025

Protocol for the development of a Core Outcome Set (COS) for reporting outcomes of clinical trials of anti-tuberculosis treatment in adults with pulmonary tuberculosis

Authors: Rebecca Thomas, Nicola L. Harman, Paula R. Williamson, Laura Bonnett, Geraint R. Davies & TB-COS Steering Committee
Source: Trials 26, 521
DOI: 10.1186/s13063-025-09224-8
 

October 2025

Low-level BTZ-043 resistance in Mycobacterium tuberculosis and cross-resistance to bedaquiline and clofazimine

Authors: Ghodousi A, Iannucci I, Saluzzo F, Dreisbach J, Mirold-Mei S, Hoelscher M, Cirillo DM.
Source: IJTLD Open, Vol 2, Issue 10
DOI: 10.5588/ijtldopen.25.0301 
 

August 2025

Designing a response-over-continuous-intervention (ROCI) randomised trial: Implementation in the Phase 2C part (duration ranging) of the PARADIGM4TB trial

Authors: Pham TM, Crook AM, Rolfe K, Phillips PPJ, Dufault SM, Quartagno M., on behalf of UNITE4TB Work Package 2
Source: Contemporary Clinical Trials, Volume 155
DOI: 108002 

14 August 2025

Studying intrapulmonary pharmacokinetics for tuberculosis treatment: a systematic review of methodology

Authors: Isabella van der Feltz , Haini Wen , Rob E Aarnoutse , Cecile Magis-Escurra , Elin M Svensson , Lindsey H M te Brake
Source: Journal of Antimicrobial Chemotherapy, Volume 80, Issue 10
DOI: 10.1093/jac/dkaf274

22 May 2025

Inclusion of patient-centered, non-microbiological endpoints and biomarkers in tuberculosis drug trials

Authors: DiNardo AR, Sabiiti W, Gillespie SH, Georghiou SB, Heinrich N, Hittel N, Taghlabi S, Carrero Longlax D, Kohli M, Panzner U, Musia C, Lange C, Vasiliu A, Arts RJW, Mandalakas AM, Ruhwald M, Stuyver LJ and van Crevel R
Source: Front. Antibiot. 4:1570989
DOI: 10.3389/frabi.2025.1570989

11 April 2025

Interoccasion variability in population pharmacokinetic models: identifiability, influence, interdependencies and derived study design recommendations

Authors: Emily Behrens, Sebastian G. Wicha
Source: Journal of Pharmacokinetics and Pharmacodynamics
DOI: 10.1007/s10928-025-09966-7 

18 March 2025

The importance of getting the dose right in the treatment of tuberculosis

Authors: Andrii Dudnyk, Wandini Lutchmun, Raquel Duarte, Christoph Lange, Elin M. Svensson
Source: Breathe 2025 21(1): 240177
DOI: 10.1183/20734735.0177-2024

Publications 2024

28 December 2024

Model-Informed Once-Daily Dosing Strategy for Bedaquiline and Delamanid in Children, Adolescents and Adults with Tuberculosis

Authors: Yu-Jou Lin, Louvina E. van der Laan, Mats O. Karlsson, Anthony J. Garcia-Prats, Anneke C. Hesseling, Elin M. Svensson
Source: Clinical Pharmacology & Therapeutics
DOI: 10.1002/cpt.3536

10 December 2024

Advances in tuberculosis biomarkers: unravelling risk factors, active disease and treatment success

Authors: Jodie A. Schildkraut, Niklas Köhler, Christoph Lange, Raquel Duarte, Stephen H. Gillespie 
Source: Breathe 2024 20(3): 240003
DOI: 10.1183/20734735.0003-2024

10 December 2024

Artificial intelligence in tuberculosis: a new ally in disease control

Authors: Mairi McClean, Traian Constantin Panciu, Christoph Lange, Raquel Duarte, Fabian Theis
Source: Breathe 2024 20(3): 240056
DOI: 10.1183/20734735.0056-2024

22 June 2024

Candidate anti-tuberculosis medicines and regimens under clinical evaluation

Authors: Michael Hoelscher, David Barros-Aguirre, Masoud Dara, Norbert Heinrich, Eugene Sun, Christoph Lange, Simon Tiberi, Charles Wells
Source: Clinical Microbiology and Infection 30 (2024) 1131-1138
DOI: 1016/j.cmi.2024.06.016

9 May 2024 

Developing biomarker assays to accelerate tuberculosis drug development: defining target product profiles

Authors: Prof Stephen H Gillespie, Andrew R DiNardo, Sophia B Georghiou, Wilber Sabiiti, Mikashmi Kohli, Ursula Panzner, Irina Kontsevaya, Norbert Hittel, Lieven J Stuyver, Jia Bin Tan, Reinout van Crevel, Christoph Lange, Thuong Nguyen Thuy Thuong, Jan Heyckendorf, Morten Ruhwald, Norbert Heinrich. 
Source: The Lancet, Microbe
DOI: 10.1016/S2666-5247(24)00085-5

22 April 2024 

Towards comprehensive clinical trials for new tuberculosis drug regimens: policy recommendations from a stakeholder analysis

Authors: Simone Villa, Pierpaolo de Colombani, Lucia Dall’Olio, Giuliano Gargioni, Mario Raviglione
Source: BMJ Global Health, Volume 9, Issue 4
DOI: 10.1136/bmjgh-2023-014630

10 February 2024

A flexible multi‐metric Bayesian framework for decision‐making in Phase II multi‐arm multi‐stage studies

Authors: Suzanne M Dufault, Angela M Crook, Katie Rolfe, Patrick P J Phillips
Source: Statistics in Medicine Vol 43, Issue 3
DOI: 10.1002/sim.9961

Publications 2023

19 September 2023

Treatment-shortening regimens for tuberculosis: updates and future priorities

Authors: Francesca Saluzzo, Victor Abiola Adepoju, Raquel Duarte, Christoph Lange, Patrick P.J. Phillips
Source: Breathe Sep 2023, 19 (3) 230028
DOI: 10.1183/20734735.0028-2023

11 July 2023

Rolling out new anti-tuberculosis drugs without diagnostic capacity

Authors: Tara Ness, Le Hong Van, Ilze Petermane, Raquel Duarte, Christoph Lange, Dick Menzies, Daniela Maria Cirillo
Source: Breathe Jun 2023, 19 (2) 230084 
DOI: 10.1183/20734735.0084-2023

13 April 2023

Standards for model-based early bactericidal activity analysis and sample size determination in tuberculosis drug development

Authors: Laurynas Mockeliunas, Alan Faraj, Rob C. van Wijk, Caryn M. Upton, Gerben van den Hoogen, Andreas H. Diacon, Ulrika S. H. Simonsson
Source: Frontiers in Pharmacology, 14. 
DOI: 10.3389/fphar.2023.1150243

11 April 2023

Tuberculosis: current challenges and beyond

Authors: Raquel Villar-Hernández, Arash Ghodousi, Olha Konstantynovska, Raquel Duarte, Christoph Lange, Mario Raviglione
Source: Breathe Mar 2023, 19 (1), 220166
DOI: 10.1183/20734735.0166-2022

Publications 2022

01 December 2022

Implementing molecular tuberculosis diagnostic methods in limited-resource and high-burden countries

Authors: Anca Vasiliu, Antonia Morita Iswari Saktiawati, Raquel Duarte, Christoph Lange, Daniela Maria Cirillo
Source: Breath, ERS publications Dec 2022, 18 (4) 220226
DOI: 10.1183/20734735.0226-2022

22 July 2022

Machine Learning and Pharmacometrics for Prediction of Pharmacokinetic Data: Differences, Similarities and Challenges Illustrated with Rifampicin

Authors: Lina Keutzer,Huifang You, Ali Farnoud, Joakim Nyberg, Sebastian G. Wicha, Gareth Maher-Edwards, Georgios Vlasakakis, Gita Khalili Moghaddam, Elin M. Svensson, Michael P. Menden, Ulrika S. H. Simonsson 
Source: Pharmaceutics 2022, 14, 1530
DOI: 10.3390/pharmaceutics14081530 

21 March 2022

Tuberculosis Treatment Monitoring and Outcome Measures: New Interest and New Strategies

Authors: Jan Heyckendorf, Sophia Georghiou, Nicole Frahm, Norbert Heinrich, Irina Kontsevaya, Maja Reimann, David Holtzman et al.
Source: Clinical Microbiology Reviews
DOI: 10.1128/cmr.00227-21

Publications 2021

1 November 2021

UNITE4TB: a new consortium for clinical drug and regimen development for TB

Authors: Boeree, M. J.; Lange, C.; Thwaites, G.; Paton, N.; de Vrueh, R.; Barros, D.; Hoelscher, M.
Source: The International Journal of Tuberculosis and Lung Disease, Volume 25, Number 11, 1 November 2021, pp. 886-889(4)
DOI: https://doi.org/10.5588/ijtld.21.0515